ArticleScientific reports2025
Elucidation and valorization of the potent activity of Commiphora myrrha gum resin extract: antimicrobial and fibroblast wound healing activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patient-derived tissue slice cultures from endoscopic biopsies as a translational ex vivo model for inflammatory bowel diseases.Clinical and experimental medicine · 2026Article
- Comparative analysis of antibacterial and antioxidant properties as well as phytochemical compositions of Moringa oleifera gum, flower, and fruit and Elaeocarpus augustifolius leaf and bark, synergistic with Pleurotus membranaceus.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the antimicrobial, antioxidant, and wound-healing properties of Commiphora myrrha (C. myrrha) resin extract and its solvent fractions. Using ethanol, methanol, hexane, and water as extraction solvents, the ethanolic extract exhibited the strongest antimicrobial activity, which was attributed to its ability to solubilize a broad range of bioactive compounds. Further fractionation revealed that the ethyl acetate sub-fraction had the highest antimicrobial efficacy, including a 23 mm inhibition zone against Klebsiella pneumoniae. Scanning Electron Microscopy analysis provided novel insights into microbial cell disruption, showing significant morphological alterations in Gram-negative bacteria and Candida albicans, while Staphylococcus aureus exhibited minimal structural damage. The DPPH assay demonstrated potent antioxidant activity in the ethyl acetate fraction (IC₅₀: 0.92 mg/mL), indicating a strong radical-scavenging capacity. Solvent polarity was found to influence both antioxidant and antimicrobial activity, with ethyl acetate emerging as the optimal extraction solvent. The crude ethanolic extract showed moderate cytotoxicity toward human dermal fibroblasts (IC₅₀: 24.53 µg/mL) but promoted wound closure by 98.4% in vitro, suggesting its biocompatibility and regenerative potential. GC-MS profiling of the ethyl acetate fraction identified 70 compounds, including Benzofuran, Elemene, and Germacra-related sesquiterpenes, providing a chemical basis for the observed biological effects. This is the first study to comprehensively link the ethyl acetate fraction of C. myrrha to both antimicrobial and wound-healing activity, supporting its development as a multifunctional therapeutic agent. The results validate its traditional use and highlight its potential in modern pharmaceutical and nutraceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.